Abstract
Background: Human regular insulin 500 (U-500) is 5 five times more concentrated than the traditional regular human insulin (U-100). Thus, every 1 ml of U-500 contains 500 units of insulin as opposed to 100 units/ml with most types of insulin.
Methods: Review of all the relevant clinical studies related to insulin U-500 until February 12, 2020.
Results: Insulin U-500 is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 has both prandial and basal actions, and can be injected as monotherapy in a convenient twice-daily regimen. Available data suggest that insulin U-500 is effective, associated with better compliance, and decreased injection pain compared with non-concentrated insulins. Its main limitations are hypoglycemia and weight gain, and the possibility of dosing errors.
Conclusions: Overall, insulin U-500 is an effective and safe treatment for patients with type 2 diabetes and insulin resistance. Randomized trials are needed to compare the long-term efficacy and safety of insulin U-500 with other forms of insulin regimens.
Keywords: Concentrated insulin U-500, pharmacokinetics, pharmacodynamics, efficacy, safety, insulin.
Current Diabetes Reviews
Title:Insulin U-500, the Practical Solution for the treatment of Patients with High Insulin Requirements
Volume: 17 Issue: 1
Author(s): Nasser Mikhail*
Affiliation:
- Department of Medicine, Endocrinology Division, Olive View-UCLA Medical Center, 14445 Olive View Dr. Sylmar, 91342,United States
Keywords: Concentrated insulin U-500, pharmacokinetics, pharmacodynamics, efficacy, safety, insulin.
Abstract:
Background: Human regular insulin 500 (U-500) is 5 five times more concentrated than the traditional regular human insulin (U-100). Thus, every 1 ml of U-500 contains 500 units of insulin as opposed to 100 units/ml with most types of insulin.
Methods: Review of all the relevant clinical studies related to insulin U-500 until February 12, 2020.
Results: Insulin U-500 is indicated in patients with type 2 diabetes who require more than 200 units of insulin per day. Insulin U-500 has both prandial and basal actions, and can be injected as monotherapy in a convenient twice-daily regimen. Available data suggest that insulin U-500 is effective, associated with better compliance, and decreased injection pain compared with non-concentrated insulins. Its main limitations are hypoglycemia and weight gain, and the possibility of dosing errors.
Conclusions: Overall, insulin U-500 is an effective and safe treatment for patients with type 2 diabetes and insulin resistance. Randomized trials are needed to compare the long-term efficacy and safety of insulin U-500 with other forms of insulin regimens.
Export Options
About this article
Cite this article as:
Mikhail Nasser *, Insulin U-500, the Practical Solution for the treatment of Patients with High Insulin Requirements, Current Diabetes Reviews 2021; 17 (1) . https://dx.doi.org/10.2174/1573399816666200408084614
DOI https://dx.doi.org/10.2174/1573399816666200408084614 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanodiamonds as a New Horizon for Pharmaceutical and Biomedical Applications
Current Drug Delivery Combination of Statin Plus Renin Angiotensin System Inhibition for the Prevention or the Treatment of Atherosclerotic Cardiovascular Disease
Current Pharmaceutical Design Vascular Stiffness: Measurements, Mechanisms and Implications
Current Vascular Pharmacology Use of STAT1 Inhibitors in the Treatment of Brain I/R Injury and Neurodegenerative Diseases
Central Nervous System Agents in Medicinal Chemistry Swimming Impacts on Pancreatic Inflammatory Cytokines, miR-146a and NF-кB Expression Levels in Type-2 Diabetic Rats
Current Diabetes Reviews The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Combination of Anti-EGFR Drugs and Other Molecular Targeted Agents as Anti-Cancer Strategy
Current Cancer Therapy Reviews Crystallization and Preliminary X-Ray Analysis of Anti-Obesity Peptide Hormone Oxyntomodulin
Protein & Peptide Letters Why Not to Use the Handgrip Test in the Assessment of Cardiovascular Autonomic Neuropathy Among Patients with Diabetes Mellitus?
Current Vascular Pharmacology Neurodegeneration in Niemann-Pick Type C Disease and Huntingtons Disease: Impact of Defects in Membrane Trafficking
Current Drug Targets Indications for Surgery and Operative Techniques in Infective Endocarditis in the Present Day
Infectious Disorders - Drug Targets Gene Therapy Approaches for Cardiovascular Diseases
Current Gene Therapy Cytotoxic Properties of Clofibrate and other Peroxisome Proliferators: Relevance to Cancer Progression
Current Medicinal Chemistry Nutrigenomics and Personalized Diet: What are the Anticipated Impacts for Research on Chronic Diseases and Public Health?
Current Pharmacogenomics and Personalized Medicine Novel Insights into Vascular Repair Mechanisms
Current Pharmaceutical Design The Antidiabetic Effects of The Bioactive Flavonoid (Kaempferol-3-O-β-D-6{P- Coumaroyl} Glucopyranoside) Isolated From Allium cepa
Recent Patents on Anti-Infective Drug Discovery Progress in Target Drug Molecules for Alzheimer's Disease
Current Topics in Medicinal Chemistry Green Factories for Biopharmaceuticals
Current Medicinal Chemistry Relationship between Fatty Acid Habitual Intake and Early Inflammation Biomarkers in Individuals with and without Type 2 Diabetes in Mexico
Endocrine, Metabolic & Immune Disorders - Drug Targets Use of Etanercept in the Treatment of Psoriasis and Psoriatic Arthritis
Reviews on Recent Clinical Trials